Cargando…

The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis

BACKGROUND: The identification of the novel targeted therapy i.e., cyclin-dependent kinases (CDKs) 4/6 inhibitor as combined with the endocrine regimen revealed a considerable capability to increase the managements’ effectivity of hormone-receptor-positive (HR+) and HER2- breast cancer (BC). OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hermansyah, Dedy, Firsty, Naufal Nandita, Alhudawy, Muhammad Nuh, Nasution, Raja Alwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Medical Sciences of Bosnia and Herzegovina 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760242/ https://www.ncbi.nlm.nih.gov/pubmed/36545458 http://dx.doi.org/10.5455/medarh.2022.76.333-342

Ejemplares similares

D-dimer as a Predictive Factor of Axillary Lymph Node Metastases in Operable Breast Cancer Patients in the Teaching Hospital of Universitas Sumatera Utara
por: Hermansyah, Dedy, et al.
Publicado: (2022)

Cat-Scratch Lymphadenitis Presenting with Right Upper Arm and Axillary Masses: a Case Report Mimicking Lymphoma and Potential Diagnostic Pitfall
por: Hermansyah, Dedy, et al.
Publicado: (2022)

High platelet count as a predicting factor of histopathological grading among invasive breast cancer individuals: a single centre experience from Indonesia
por: Hermansyah, Dedy, et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers
por: Hermansyah, Dedy, et al.
Publicado: (2022)

Hormonal treatments for endometriosis: The endocrine background
por: Vannuccini, Silvia, et al.
Publicado: (2021)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer: a systematic review
por: Zhu, Linhui, et al.
Publicado: (2022)

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
por: Wei, Qiran, et al.
Publicado: (2023)

Simultaneous Quantification of Steroid Hormones Using hrLC-MS in Endocrine Tissues of Male Rats and Human Samples
por: Bordanaba-Florit, Guillermo, et al.
Publicado: (2022)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
por: Zhang, Qing Yuan, et al.
Publicado: (2020)

Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer
por: Horii, R, et al.
Publicado: (2007)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
por: Presti, Daniele, et al.
Publicado: (2019)

Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome
por: Dahlgren, Jovanna, et al.
Publicado: (2022)

Hormone Production in Endocrine Tumours
por: Abelson, Denis
Publicado: (1958)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis
por: Nabieva, Naiba, et al.
Publicado: (2023)

Efficacy and safety of palbociclib plus endocrine therapy for patients with HR(+)/HER2(−) advanced breast cancer in real-world clinical practice
por: Zhong, Bingqian, et al.
Publicado: (2022)

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
por: Mittal, Abhenil, et al.
Publicado: (2023)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Aging under endocrine hormone regulation
por: Xing, Yutong, et al.
Publicado: (2023)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
por: Davie, Alison, et al.
Publicado: (2023)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
por: Attia, Yasmin M., et al.
Publicado: (2020)

Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
por: Machado, Marcel Cerqueira Cesar
Publicado: (2012)

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
por: O’Sullivan, Ciara C
Publicado: (2015)

The Olfaction Ability of Medical Detection Canine to Detect Prostate Cancer From Urine Samples: Progress Captured in Systematic Review and Meta-Analysis
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer
por: Wang, Wei, et al.
Publicado: (2016)

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2013)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_si9imrqlj4ur87d9cpeg57eik4